Curcumin-loaded cationic solid lipid nanoparticles as a potential platform for the treatment of skin disorders.

Curcumin (CUM) possesses therapeutic activity against diverse skin disorders (SD); however, its clinical use faces many challenges related to physicochemical and bioavailability characteristics, that can be solve designing a new drug delivery system for CUM to treat SD. Cationic solid lipid nanoparticles (CSLN) were developed and physicochemically analyzed. The ingredients and methods adopted in this study promoted the successful preparation of CSLN with a monodispersed particle size of 218.4-238.6 nm and a polydispersity index of 0.156-0.350. A differential scanning calorimetric assay demonstrated that CUM was incorporated. The atomic force microscopy images showed uniform spherical particles, and light scattering technique confirmed the size of the particles. The zeta potential of the CSLN was +23.1 to +30.1 mV, which is important in targeting the drug to the diseased tissue that presents unregulated apoptosis. All formulations behaved as controlled drug delivery systems of CUM, as demonstrated by an in vitro drug release study, which delayed the start of drug release from formulations. At the end of the experiment, the formulations had released 14.74-21.23% of the incorporated CUM. In conclusion, the results suggest the potential of this CSLN as a controlled CUM delivery system for the treatment of SD.